GWAS |
- 3-month functional outcome in ischaemic stroke (modified Rankin score) ( 30582445)
- Excessive daytime sleepiness ( 27992416)
- Sleep traits (multi-trait analysis) ( 27992416)
- Type 2 diabetes ( 30297969)
|
- anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028)
- Autism spectrum disorder or schizophrenia ( 28540026)
- Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) ( 23453885)
- Bipolar disorder ( 31043756)
- Bipolar I disorder ( 31043756)
- Chronic kidney disease ( 26420894)
- Cognitive ability, years of educational attainment or schizophrenia (pleiotropy) ( 31374203)
- Copper levels ( 26025379)
- FEV1 ( 30804560)
- General risk tolerance (MTAG) ( 30643258)
- Hepatitis B ( 22004137)
- Laryngeal squamous cell carcinoma ( 25194280)
- Lung function (FVC) ( 30804560)
- Metabolite levels ( 23823483)
- Night sleep phenotypes ( 27126917)
- Rosacea symptom severity ( 29771307)
- Schizophrenia ( 28991256 25056061 29483656 30285260)
- Tenofovir clearance in HIV infection ( 26148204)
- Thiazide-induced adverse metabolic effects in hypertensive patients ( 23400010)
- Waist circumference adjusted for BMI (smoking interaction) ( 28443625)
|